Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / PGNX - Progenics up 6% on PyL data in prostate cancer


PGNX - Progenics up 6% on PyL data in prostate cancer

  • Progenics Pharmaceuticals (PGNX +5.9%) is up on below-average volume on the heels of results from a Phase 2/3 clinical trial, OSPREY, evaluating PSMA-targeted PET imaging agent PyL in men with high-risk metastatic prostate cancer and an investigator-sponsored study assessing PyL in men with biochemically recurrent prostate cancer. The data were presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Anaheim, CA.
  • More news on: Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Progenics Pharmaceuticals Inc.
Stock Symbol: PGNX
Market: NASDAQ
Website: progenics.com

Menu

PGNX PGNX Quote PGNX Short PGNX News PGNX Articles PGNX Message Board
Get PGNX Alerts

News, Short Squeeze, Breakout and More Instantly...